### Introduction to Anixa Biosciences
SAN JOSE, Calif. — On May 1, 2026, Anixa Biosciences, Inc., a forward-thinking biotechnology company, announced an upcoming feature on Bloomberg TV. The segment will showcase an interview with Dr. Amit Kumar, the Chairman and CEO, scheduled to air on May 2 at 7 PM ET. This airing marks an exciting opportunity for viewers to gain insights into the company’s innovative approaches to cancer treatment and prevention. Anixa focuses on harnessing novel therapeutic technologies to address some of the most challenging forms of cancer.
### The Capital-Efficient Business Model
In the interview, Dr. Kumar will delve into Anixa’s capital-efficient business model, which has been instrumental in its journey. By partnering with leading research institutions like the Cleveland Clinic and the Moffitt Cancer Center, Anixa is able to leverage shared resources and expertise across various stages of drug development. This collaborative methodology not only reduces financial risk but also enhances the innovation pipeline, enabling the company to concentrate efforts on groundbreaking therapies for cancer.
### Breakthrough in Breast Cancer Vaccine Trials
One of the highlights discussed will be Anixa’s promising breast cancer vaccine, which recently met its primary endpoints in a Phase 1 clinical trial. Impressively, 74% of the participants exhibited protocol-defined immune responses, a significant milestone that underscores the potential impact of this vaccine on patient outcomes. The results showcase the company’s commitment to using immune response activation as a mechanism for breast cancer prevention and treatment, marking a step forward in oncology.
### Innovations in Ovarian Cancer Treatments
Additionally, the conversation will touch upon Anixa’s groundbreaking ovarian cancer therapy, lira-cel, which employs a novel CAR-T technology. In ongoing Phase 1 trials, lira-cel has demonstrated positive survival data, further validating Anixa’s strategic focus on innovative immunotherapies. This treatment, developed with Moffitt Cancer Center, utilizes chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by binding directly to tumor cells, potentially improving efficacy in treating ovarian cancer.
### Collaboration with Prestigious Institutions
Anixa’s partnership with the Moffitt Cancer Center, a recognized leader in cancer immunotherapy, exemplifies its strategic vision. Moffitt’s expertise in CAR-T and tumor-infiltrating lymphocytes (TILs) further solidifies Anixa’s innovative approach. Such alliances allow Anixa to remain at the forefront of cancer research and treatment modalities, facilitating rapid advancements against complex malignancies.
### The Broader Vaccine Portfolio
Beyond breast and ovarian cancer, Anixa is also expanding its vaccine portfolio in collaboration with the Cleveland Clinic. The company aims to develop treatments for other high-incidence cancers, including lung, colon, and prostate cancer. These vaccines focus on “retired” proteins, which are expressed in certain cancers, allowing targeted immune responses. This research not only contributes to Anixa’s core mission but also establishes a robust platform to combat various forms of cancer.
### A Model for Future Innovation
Anixa’s unique model of development through collaboration emphasizes the potential of synergistic partnerships in biotechnology. As the company continues to evaluate emerging technologies, it stands poised to explore additional avenues for advancement in cancer treatment. This iterative approach permits Anixa to expand its research network while maintaining a vigilant eye on novel therapeutic strategies.
### Engaging with the Community
In addition to the televised interview, Anixa actively engages with the broader community through its digital platforms. Interested parties can learn more about the company’s initiatives by visiting the official website or following Anixa on various social media channels.
### Looking Ahead
As the company pushes forward, it is essential to acknowledge the forward-looking statements that define its strategic outlook. Investors and stakeholders are advised to consider potential risks and uncertainties that could influence Anixa’s performance and results. The company is committed to transparent communication regarding its progress and developments.
### Contact Information
For more information, stakeholders can reach out to Mike Catelani, Anixa’s President, COO, and CFO, to discuss inquiries further. Engaging with Anixa’s leadership may provide additional insights into the company’s innovative strategies and future endeavors.
